Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement stock option awards on April 1, 2026, granting up to 228,500 shares to eight new employees under its 2023 Inducement Plan.
The options vest over four years: 25% at one year, then monthly vesting over 36 months, subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SNDX
-3.42%
-3.42%News Effect
On the day this news was published, SNDX declined 3.42%, reflecting a moderate negative market reaction.
This announcement details routine equity compensation, granting stock options for 228,500 shares to ...
Analysis
This announcement details routine equity compensation, granting stock options for 228,500 shares to eight new employees under the 2023 Inducement Plan, vesting over 4 years with a 25% first-year cliff and monthly vesting thereafter. It follows a prior inducement grant disclosed on Mar 04, 2026, reinforcing a consistent approach to attracting and retaining talent. Investors may focus more on revenue growth, commercial execution, and upcoming trial milestones when assessing the broader equity story.
Key Figures
Inducement option grants:228,500 sharesNew employees:8 employeesVesting period:4 years+5 more
8 metrics
Inducement option grants228,500 sharesStock options granted to eight new employees on April 1, 2026
New employees8 employeesRecipients of inducement stock option awards
Vesting period4 yearsTotal vesting term for inducement stock options
Initial cliff vesting25%Options vest on one-year anniversary of vesting commencement date
Monthly vesting fraction1/48thPortion of options vesting monthly after first year
Subsequent vesting duration36 monthsMonthly vesting period following the first-year cliff
Price change pre-news5.32%Share price move in the last 24 hours before this release
52-week performance193.12% above lowPrice versus 52-week low before this announcement
CEO scheduled for fireside chat at Guggenheim biotech summit with webcast access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
SNDX has generally shown mild positive reactions to corporate updates, with the strongest moves tied to financial results rather than routine announcements.
Recent Company History
Over the last few months, SNDX news flow has included recurring inducement grants, investor conference participation, and detailed 2025 financial results. The prior inducement award on Mar 04, 2026 had minimal price impact, while Q4/FY 2025 earnings on Feb 26, 2026 coincided with a stronger positive move. Conference participation headlines in February saw small directional gains or losses. Today’s inducement grants fit the pattern of routine compensation updates against a backdrop of commercial ramp for Revuforj and Niktimvo.
"Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement planfinancial
"to eight new employees under the Company's 2023 Inducement Plan."
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
stock optionsfinancial
"The stock options will vest over four years, with 25% of the underlying shares vesting"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre Syndax Pharmaceuticals, Inc. sklahre@syndax.com Tel 781.684.9827
FAQ
What did Syndax (SNDX) announce on April 1, 2026 about inducement grants?
Syndax granted inducement stock options to eight new employees totaling up to 228,500 shares. According to the company, the awards were made under the 2023 Inducement Plan and intended to recruit new personnel.
How do the Syndax SNDX inducement options vest and when do they start?
The options vest over four years with 25% vesting at one year and monthly thereafter. According to the company, 1/48th vests each month over the remaining 36 months, subject to continued service.
How many employees received Syndax (SNDX) inducement awards on April 1, 2026?
Eight new employees received inducement awards under the 2023 Inducement Plan. According to the company, the grants are intended as hiring inducements for newly hired staff.
What is the total share count of the SNDX inducement awards and how might that affect shareholders?
The awards total up to 228,500 shares of common stock granted as options. According to the company, the options are standard inducements; the release did not state any immediate cash impact or dilution percentage.
Under which plan were the Syndax (SNDX) inducement stock options granted?
The options were granted under the company's 2023 Inducement Plan to comply with Nasdaq rules. According to the company, the plan permits awards to newly hired employees as recruiting inducements.
